July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Four-Year Incidence and Risk Factors of Age-Related Macular Degeneration: the ALIENOR Study
Author Affiliations & Notes
  • Audrey Cougnard-Gregoire
    Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, team LEHA, UMR 1219, Bordeaux, F-33000, France
  • Valentine Saunier
    Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, team LEHA, UMR 1219, Bordeaux, F-33000, France
    CHU de Bordeaux, Service d’Ophtalmologie, Bordeaux, F-33000, France
  • Benedicte MJ Merle
    Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, team LEHA, UMR 1219, Bordeaux, F-33000, France
  • Marie-Noelle Delyfer
    Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, team LEHA, UMR 1219, Bordeaux, F-33000, France
    CHU de Bordeaux, Service d’Ophtalmologie, Bordeaux, F-33000, France
  • Marie B Rougier
    CHU de Bordeaux, Service d’Ophtalmologie, Bordeaux, F-33000, France
  • Philippe Amouyel
    Lille University, Inserm, Lille University Hospital, Institut Pasteur de Lille, U1167 - RID-AGE - Risk factors and molecular determinants of aging-related diseases; Labex Distalz, Lille, France
  • Jean-Charles Lambert
    Lille University, Inserm, Lille University Hospital, Institut Pasteur de Lille, U1167 - RID-AGE - Risk factors and molecular determinants of aging-related diseases; Labex Distalz, Lille, France
  • Jean-François Dartigues
    Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, team LEHA, UMR 1219, Bordeaux, F-33000, France
  • Jean-Francois Korobelnik
    Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, team LEHA, UMR 1219, Bordeaux, F-33000, France
    CHU de Bordeaux, Service d’Ophtalmologie, Bordeaux, F-33000, France
  • Cecile DelCourt
    Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, team LEHA, UMR 1219, Bordeaux, F-33000, France
  • Footnotes
    Commercial Relationships   Audrey Cougnard-Gregoire, Laboratoires Théa (R); Valentine Saunier, None; Benedicte Merle, Bausch & Lomb (R), Horus Pharma (C), Laboratoires Théa (R), St Hubert (C); Marie-Noelle Delyfer, Allergan (C), Bausch &Lomb (C), Bayer (C), Laboratoires Théa (C), Novartis (C); Marie Rougier, Allergan (C), Bausch & Lomb (C), Bayer (C), Laboratoires Théa (C), Novartis (C); Philippe Amouyel, None; Jean-Charles Lambert, None; Jean-François Dartigues, None; Jean-Francois Korobelnik, Alcon (C), Alimera (C), Allergan (C), Baush&Lomb (C), Bayer (C), Beaver Visitec (C), Boehringer-Ingelheim (C), Essilor (C), Kanghong (C), Krys (C), NanoRetina (C), Novartis (C), Roche (C), Thea (C), Thrombogenics (C), Zeiss (C); Cecile DelCourt, Allergan. (C), Bausch+Lomb (C), Laboratoires Théa (C), Novartis (C), Roche (C)
  • Footnotes
    Support  Fondation Voir et Entendre ; Laboratoires Théa ; Université de Bordeaux ; agence nationale de la Recherche (ANR-VISA 2010-PRSP-011)
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5537. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Audrey Cougnard-Gregoire, Valentine Saunier, Benedicte MJ Merle, Marie-Noelle Delyfer, Marie B Rougier, Philippe Amouyel, Jean-Charles Lambert, Jean-François Dartigues, Jean-Francois Korobelnik, Cecile DelCourt; Four-Year Incidence and Risk Factors of Age-Related Macular Degeneration: the ALIENOR Study. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5537.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Few population-based prospective studies of age-related macular degeneration (AMD) have been conducted in Europe. The objective was to describe the 4-year cumulative incidence and associated risk factors of AMD in French elderly subjects.

Methods : The Alienor study is a population-based cohort study of 963 residents of Bordeaux (France), aged 73 years or more at baseline. Of those, 829 were at risk for incident AMD and 659 (79.5%) subjects were followed up for a mean duration of 3.8 years (SD 1.1 years). AMD was graded in four exclusive stages (early AMD 1, early AMD 2, atrophic AMD and neovascular AMD) on the basis of retinal fundus photographs and spectral domain optical coherence tomography.

Results : The cumulative incidence was 26.9% (95% confidence interval (CI): 22.7-31.0) for early AMD and 6.8% (95% CI: 4.9-8.8) for advanced AMD. The incidence rates of distinct and indistinct soft drusen and pigmentary abnormalities were 19.2%, 12.1% and 22.0%, respectively. Incident advanced AMD was 0.6% in participants without any AMD at baseline, 13.8% in those with early AMD1 and 28.3% in those with early AMD 2. In multivariate analysis, progression from early to advanced AMD was significantly associated with AMD grade in the fellow eye (Hazard Ratio (HR): 13.1 to 22.3 according to stage, p<0.0001), having smoked at least 20 pack-years (HR: 2.9, 95% CI: 1.3-6.4, p=0.002) and CFH Y402H (HR: 2.6, 95 %: 1.2-5.7 for TC genotype and 1.72, 95% CI: 0.73-4.10 for CC genotype, p=0.003). Incidence of early AMD was higher in subjects with early AMD in the fellow eye (HR: 2.6, 95 % CI: 1.6-4.1 for early AMD 1 and 5.5, 95 % CI: 3.2-9.5 for early AMD 2, p<0.001). Plasma high density lipoprotein (HDL)-cholesterol was associated with increased risk for incident early AMD in age- and gender-adjusted model (HR=1.9, 95%: 1.3-2.0, p=0.003), but this association was not statistically significant in the multivariate model (HR=1.6, 95% CI: 0.9-2.6, p=0.09).

Conclusions : The incidence of AMD was similar to those observed in other populations of European descent. Risk factors appear to be different for between the incident early AMD and the progression from early to advanced AMD.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×